Targeted drugs for lung cancer with bone metastasis include gefitinib, crizotinib, bevacizumab, and erlotinib. 1. Non-small cell lung cancer with EGFR gene mutation: including first-generation gefitinib, erlotinib and erlotinib, second-generation afatinib and third-generation ositinib. Gefitinib is preferred for patients with bone metastases from non-small cell lung cancer who carry sensitive mutations in the EGFR gene, and the anti-tumor therapy of this drug also significantly improves the occurrence of pathological fractures. Ositinib is recommended for patients who have progressed after first-generation treatment and are positive for T790M mutation. 2. Non-small cell lung cancer with positive ALK or ROS1 fusion gene can be treated with crizotinib. After crizotinib resistance, second-generation ALK inhibitor sertitinib can be chosen. 3. VEGF-targeted therapy: for example, bevacizumab, the combination of bevacizumab and chemotherapy can improve the therapeutic efficacy of non-squamous non-small cell lung cancer and prolong the survival of patients. 4. Small molecule anti-VEGFR multi-target tyrosine kinase inhibitors, such as amlotinib, can also be used in the third-line treatment of patients with bone metastases. Lung cancer with bone metastasis is a systemic disease, so it should be treated with comprehensive treatment mainly based on systemic therapy, including surgery, radiotherapy, chemotherapy for pain relief, bisphosphonates and psychological support therapy. Bone metastasis of lung cancer should be treated with appropriate systematic comprehensive treatment under the guidance of specialists, and the above medicines should be used under the guidance of doctors after evaluating the condition, and blind self-medication should be avoided.